Financial analysis of chronic transfusion for stroke prevention in sickle cell disease
Authors:
Open Access
- 1 October 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 96 (7) , 2369-2372
Abstract
Chronic red blood cell transfusion can prevent many of the manifestations of sickle cell disease. The medical costs of chronic transfusion and management of associated side effects, especially iron overload, are considerable. This study was undertaken to evaluate the financial impact of chronic transfusion for stroke prevention in patients with sickle cell anemia. Outpatient charges pertaining to hospital-based Medicare uniform bill (UB-92) codes, professional fees, and iron chelation were evaluated. Data were collected on 21 patients for a total of 296 patient months (mean, 14; median, 14 months/patient). Charges ranged from $9828 to $50 852 per patient per year. UB-92, chelation, and physician-related charges accounted for 53%, 42%, and 5% of total charges, respectively. Of UB-92 charges, 58% were associated with laboratory fees and 16% were related to the processing and administration of blood. Charges for patients who required chelation therapy ranged from $31 143 to $50 852 per patient per year (mean, $39 779; median, $38 607). Deferoxamine accounted for 71% of chelation-related charges, which ranged from $12 719 to $24 845 per patient per year (mean, $20 514; median, $21 381). The financial impact of chronic transfusion therapy for sickle cell disease is substantial with charges approaching $400 000 per patient decade for patients who require deferoxamine chelation. These data should be considered in reference to cost and efficacy analyses of alternative therapies for sickle cell disease, such as allogeneic bone marrow transplantation.Keywords
This publication has 19 references indexed in Scilit:
- The Costs of Children With Sickle Cell AnemiaJournal of Pediatric Hematology/Oncology, 1998
- Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusionsThe Journal of Pediatrics, 1995
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995
- Effects of a long-term transfusion regimen on sickle cell-related illnessesThe Journal of Pediatrics, 1994
- Bone-marrow transplantation in sickle-cell anaemia: why so few so late?The Lancet, 1992
- Stroke in a cohort of patients with homozygous sickle cell diseaseThe Journal of Pediatrics, 1992
- High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell diseaseThe Journal of Pediatrics, 1991
- Prophylaxis with Oral Penicillin in Children with Sickle Cell AnemiaNew England Journal of Medicine, 1986
- Neurological complications of sickle cell anemiaJournal of Pediatric Hematology/Oncology, 1982
- Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidentsThe Journal of Pediatrics, 1980